Joseph Pearlberg - Infinity Pharmaceuticals Insider

INFI -- USA Stock  

USD 1.96  0.07  3.45%

Vice President - Clinical Development
Dr. Joseph Pearlberg, M.D. Ph.D., serves as Vice President Clinical Development of the Company
  President Since 2017  Ph.D    
617-453-1000  http://www.infi.com
Joseph Pearlberg joined Infinity in 2014 and has 25 years of experience in research and medicine. Prior to joining Infinity, Dr. Pearlberg worked at Sanofi from 2010 to 2014 where he held various roles of increasing responsibility within the clinical development organization. Prior to that, Dr. Pearlberg held a postdoctoral fellowship at Harvard Medical School from 2002 to 2010. During his career, he also held various medical and research positions at Dana Farber Cancer Center and Massachusetts General Hospital. Additionally, Dr. Pearlberg was a Genentech Research Fellow from 1997 to 1999. He earned a M.D. from University of California, San Francisco, a Ph.D. in molecular biology from Harvard University and a B.A. from University of Pennsylvania.

Management Efficiency

The company has return on total asset (ROA) of (28.88) % which means that it has lost $28.88 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (68.47) % meaning that it created substantial loss on money invested by shareholders.

Similar Executives

Entity Summary

Infinity Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for people with cancer in the United States. Infinity Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts. Infinity Pharmaceuticals operates under Biotechnology classification in USA and traded on BATS Exchange. It employs 22 people.Infinity Pharmaceuticals (INFI) is traded on BATS Exchange in USA. It is located in MASSACHUSETTS U.S.A and employs 22 people. Infinity Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.

Infinity Pharmaceuticals Leadership Team

Joseph Pearlberg, President, Ph.D
Melissa Hackel, President, MBA
William Bertrand, President
Vito Palombella, EVP
Jeffrey Berkowitz, Director
Lawrence Bloch, President, MBA
Norman Selby, Director, MBA
Jose Baselga, Director, Ph.D
Michael Venuti, Director, Ph.D
Michael Kauffman, Director
Eric Lander, Director, Ph.D
David Beier, Director
Julian Adams, President
Anthony Evnin, Director, Ph.D
Gwendolyn Fyfe, Director
Sujay Kango, President, MBA
Ian Smith, Director
Adelene Perkins, Chairman, MBA

Stock Performance Indicators

Current Sentiment - INFI

Infinity Pharmaceuticals Investor Sentiment
Most of Macroaxis users are currently bullish on Infinity Pharmaceuticals. What is your judgment towards investing in Infinity Pharmaceuticals? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Build Optimal Portfolios

Align your risk with return expectations
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please also check Risk vs Return Analysis. Please also try Content Syndication module to quickly integrate customizable finance content to your own investment portal.